Jinhai Med Tech (02225) announced its financial results for the year ended December 31, 2025. The group recorded revenue of SGD 46.276 million, a decrease of 7.89% compared to the previous year. The loss attributable to the company's owners was SGD 17.08 million, which represents a reduction of 4.9% year-on-year. The loss per share was SGD 0.33 cents.

According to the announcement, the group incurred a total loss of SGD 17.4 million for the 2025 fiscal year, compared to a loss of SGD 18.3 million in the 2024 fiscal year. This reduction in the overall loss was primarily due to a decrease in administrative expenses of SGD 7.5 million, which was partially offset by a decline in gross profit.